ViVac Pharma Ltd., a pioneering synthetic biology company advancing RNA–Lipid Nanoparticle (LNP) immunotherapies, announces ...
LipidVerse 2025, a landmark one-day conference dedicated to exploring cutting-edge advancements in lipid-based technologies ...
A new lipid nanoparticle could make mRNA vaccines more powerful and potentially lower the cost per vaccine dose. (Nanowerk News) In studies in mice, the researchers showed that an mRNA influenza ...
The study was published in Nature Biotechnology last month and marks a shift in scientists’ understanding of how to efficiently cure specific diseases.
At the conference, Acuitas' Chief Scientific Officer, Dr. Ying Tam, showcased the company's Next-Generation LNP advancements, a comprehensive approach that uses multiple technologies and strategies to ...
A joint Singaporean-Chinese research team has developed an Evans Blue-modified lipid nanoparticle platform that directs mRNA ...
Key presentation unveiled Acuitas' Next-Generation LNP Advancements, which is designed to enhance potency and safety, expand delivery beyond the liver, and enable broader therapeutic impact ...
The global market for lipid nanoparticles (LNPs) hit $786 million in 2024 and is projected to grow 14% a year to 2030, driven by their increasing popularity as drug delivery vehicles.[1] The success ...
1don MSN
Teens may have come up with a new way to detect, treat Lyme disease using CRISPR gene editing
To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...
Preclinical mRNA therapy using peptibodies enhances bacterial clearance and immune response in multidrug-resistant pneumonia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback